NCT00062699终止4 期
A Phase IV, Prospective, Randomized, Active-Controlled, Double-Blind, Double-Dummy, Multi-Center Study to Evaluate the Survival Benefits of Zemplar Relative to Calcijex in Subjects With Stage V Chronic Kidney Disease on Hemodialysis
适应症
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 终止
- 发起方
- Abbott
- 入组人数
- 2,200
- 试验地点
- 116
- 主要终点
- Time to Death
研究概览
简要总结
To evaluate the survival benefit associated with Zemplar therapy as compared to Calcijex for the treatment of secondary hyperparathyroidism in subjects with Stage V chronic kidney disease on hemodialysis as measured by time to death.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 20 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
结局指标
主要结局
Time to Death
次要结局
- Number of days hospitalized for any cause
- Time to Death attributable to cardiovascular disease
- Number of hospitalizations for any cause
- Number of hospitalizations due to cardiovascular disease
- Number of days hospitalized due to cardiovascular disease
研究者
研究点 (116)
Loading locations...
相似试验
已完成
不适用
Long-Term Therapy Outcomes When Treating Chronic Kidney Disease (CKD) Patients With Paricalcitol in German and Austrian Clinical PracticeKidney InsufficiencySecondary HyperparathyroidismNCT01083849AbbVie (prior sponsor, Abbott)761
已完成
1 期
A Study to Investigate the Effects of Zelicapavir (EDP-938) on QTc Interval in Healthy AdultsRSV InfectionQTc IntervalNCT06601192Enanta Pharmaceuticals, Inc72
已完成
2 期
A Study to Examine the Use of Zemplar to Increase Serum Calcium Levels in ICU SubjectsHypocalcemiaNCT00053378Abbott45
已完成
4 期
A Study of Zemplar® Injection and Hectorol® Injection on Intestinal Absorption of Calcium in Chronic Kidney DiseaseChronic Kidney Disease, Stage 5Secondary HyperparathyroidismNCT00257920Abbott41
已完成
3 期
A Study to Test Whether ZS (Sodium Zirconium Cyclosilicate) Can Reduce the Incidence of Increased Blood Potassium Levels Among Dialized Patients.HyperkalemiaNCT03303521AstraZeneca196